Jessica Nance, MD, MS, discusses maximizing gene therapy efficiency by selecting vectors for gene size, tissue targeting, and low exposure, and focusing on precise promoters for expression. This is a ...

Gene therapy is reshaping modern medicine, offering the potential for lasting, even curative treatments for a wide range of ...

Cell and gene therapies rely on engineered viruses to deliver them to their cellular destinations. While the progress of these types of medicines is evident in a growing number of FDA product ...

We use the AdenoX Rapid Titer kit (Clontech now Takara Bio) for this service. This immunohistochemical assay involves making 3 serials dilutions of the virus and infecting 6 wells of a 24-well plate ...

Patients in a Phase I/II clinical trial conducted by UMass Chan Medical School of a dual vector gene therapy for GM2 gangliosidosis, which includes Tay-Sachs and Sandhoff diseases, exhibited a ...

A new study describes the use of artificial intelligence (AI) in designing a new generation of capsids, the structures that envelop genetic material of adeno-associated viruses (AAV), to improve gene ...

Gene therapy developers targeting diseases requiring high dose therapies face a challenge. Current vector production cell lines and genetic manipulation techniques are too costly for large-scale ...

Ring Therapeutics®, a life sciences company pioneering a new class of targeted medicines, today announced new data on its Vector Conjugate platform and VectorBricks™ in vitro manufacturing technology.

Patients in a Phase I/II clinical trial conducted by UMass Chan Medical School of a dual vector gene therapy for GM2 gangliosidosis, which includes Tay-Sachs and Sandhoff diseases, exhibited a ...

Viralgen, the gene therapy CDMO coined by Bayer’s Asklepios BioPharmaceutical, is wading into commercial waters. The Spanish contractor on Wednesday said it cut the ribbon on the first $83 million ...